Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1965 1
1969 2
1970 1
1971 1
1977 2
1979 2
1981 1
1982 1
1983 1
1984 1
1985 3
1987 3
1988 3
1989 6
1991 1
1992 2
1996 2
1998 3
1999 2
2000 2
2001 2
2002 5
2003 5
2004 5
2005 2
2006 1
2007 3
2008 5
2009 5
2010 2
2011 5
2012 9
2013 7
2014 9
2015 9
2016 11
2017 11
2018 8
2019 6
2020 11
2021 15
2022 17
2023 16

Text availability

Article attribute

Article type

Publication date

Search Results

181 results

Results by year

Filters applied: . Clear all
Page 1
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.
Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Ho PJ, Pérez-Simón JA, Chen AI, Nastoupil LJ, von Tresckow B, Ferreri AJM, Teshima T, Patten PEM, McGuirk JP, Petzer AL, Offner F, Viardot A, Zinzani PL, Malladi R, Zia A, Awasthi R, Masood A, Anak O, Schuster SJ, Thieblemont C. Fowler NH, et al. Among authors: kolstad a. Nat Med. 2022 Feb;28(2):325-332. doi: 10.1038/s41591-021-01622-0. Epub 2021 Dec 17. Nat Med. 2022. PMID: 34921238 Clinical Trial.
T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes.
Ali M, Giannakopoulou E, Li Y, Lehander M, Virding Culleton S, Yang W, Knetter C, Odabasi MC, Bollineni RC, Yang X, Foldvari Z, Böschen ML, Taraldsrud E, Strønen E, Toebes M, Hillen A, Mazzi S, de Ru AH, Janssen GMC, Kolstad A, Tjønnfjord GE, Lie BA, Griffioen M, Lehmann S, Osnes LT, Buechner J, Garcia KC, Schumacher TN, van Veelen PA, Leisegang M, Jacobsen SEW, Woll P, Olweus J. Ali M, et al. Among authors: kolstad a. Nat Biotechnol. 2022 Apr;40(4):488-498. doi: 10.1038/s41587-021-01089-x. Epub 2021 Dec 6. Nat Biotechnol. 2022. PMID: 34873326 Free PMC article.
Radioimmunotherapy of Non-Hodgkin B-cell Lymphoma: An update.
Cicone F, Santo G, Bodet-Milin C, Cascini GL, Kraeber-Bodéré F, Stokke C, Kolstad A. Cicone F, et al. Among authors: kolstad a. Semin Nucl Med. 2023 May;53(3):413-425. doi: 10.1053/j.semnuclmed.2022.12.006. Epub 2023 Jan 10. Semin Nucl Med. 2023. PMID: 36635112 Review.
[Skier's eye].
Opsahl R Jr, Kolstad A. Opsahl R Jr, et al. Among authors: kolstad a. Tidsskr Nor Laegeforen. 1969 Mar 15;89(6):414-5. Tidsskr Nor Laegeforen. 1969. PMID: 5792121 Norwegian. No abstract available.
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.
Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, Montano-Almendras CP, Husby S, Freiburghaus C, Ek S, Pedersen A, Niemann C, Räty R, Brown P, Geisler CH, Andersen MK, Guldberg P, Jerkeman M, Grønbæk K. Eskelund CW, et al. Among authors: kolstad a. Blood. 2017 Oct 26;130(17):1903-1910. doi: 10.1182/blood-2017-04-779736. Epub 2017 Aug 17. Blood. 2017. PMID: 28819011 Free article.
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.
Eskelund CW, Kolstad A, Jerkeman M, Räty R, Laurell A, Eloranta S, Smedby KE, Husby S, Pedersen LB, Andersen NS, Eriksson M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Workman CT, Garde C, Elonen E, Brown P, Grønbaek K, Geisler CH. Eskelund CW, et al. Among authors: kolstad a. Br J Haematol. 2016 Nov;175(3):410-418. doi: 10.1111/bjh.14241. Epub 2016 Jul 5. Br J Haematol. 2016. PMID: 27378674 Free article.
Cross-modal coherent registration of whole mouse brains.
Qu L, Li Y, Xie P, Liu L, Wang Y, Wu J, Liu Y, Wang T, Li L, Guo K, Wan W, Ouyang L, Xiong F, Kolstad AC, Wu Z, Xu F, Zheng Y, Gong H, Luo Q, Bi G, Dong H, Hawrylycz M, Zeng H, Peng H. Qu L, et al. Among authors: kolstad ac. Nat Methods. 2022 Jan;19(1):111-118. doi: 10.1038/s41592-021-01334-w. Epub 2021 Dec 9. Nat Methods. 2022. PMID: 34887551
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.
Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, Eriksson M, Nordström M, Kimby E, Boesen AM, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Akerman M, Ehinger M, Sundström C, Langholm R, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E; Nordic Lymphoma Group. Geisler CH, et al. Among authors: kolstad a. Blood. 2008 Oct 1;112(7):2687-93. doi: 10.1182/blood-2008-03-147025. Epub 2008 Jul 14. Blood. 2008. PMID: 18625886 Free PMC article. Clinical Trial.
A systematic safety pipeline for selection of T-cell receptors to enter clinical use.
Foldvari Z, Knetter C, Yang W, Gjerdingen TJ, Bollineni RC, Tran TT, Lund-Johansen F, Kolstad A, Drousch K, Klopfleisch R, Leisegang M, Olweus J. Foldvari Z, et al. Among authors: kolstad a. NPJ Vaccines. 2023 Aug 22;8(1):126. doi: 10.1038/s41541-023-00713-y. NPJ Vaccines. 2023. PMID: 37607971 Free PMC article.
181 results